Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Respiratory Medicine   Commentary on Twitter NEW Research—Pirfenidone slowed the rate of decline of FVC over time in patients with RA-ILD* Being presented at #ERSCongress, ALERT 3 session, Sept 5 from […]

The post Phase 2 RCT | Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease. appeared first on Links Medicus.